Nemaura Medical

The sugarBEAT CGM. [Image from Nemaura Medical]Nemaura Medical (Nasdaq:NMRD) announced today that it received Saudi Food and Drug Authority (SFDA) approval for its sugarBEAT sensor.

The company develops daily, non-invasive, disposable, wearable glucose sensors. It also offers digital diabetes management tools and earlier this year added CGM-guided insulin dose titration to its offerings.

Nemaura’s sugarBEAT, a CE-marked device, offers non-invasive, flexible continuous glucose monitoring (CGM). It provides actionable insights derived from real-time glucose measurements and daily glucose trend data. It could help people with diabetes and pre-diabetes better manage, reverse and prevent the onset of the chronic condition.

Loughborough, England-based Nemaura submitted an FDA premarket approval application for sugarBEAT in the U.S.

Get the full story at our sister site, Drug Delivery Business News.

The proBEAT sensor. [Image from Nemaura Medical]Nemaura Medical (Nasdaq:NMRD) announced that it brought in $6.5 million in non-dilutive funding through a clean debt facility.

The Loughborough, England-based company said its debt facility features no warrants or convertible elements. It comes from the company’s existing lender.

Nemaura Medical did not list an intended use for the added funds. The company develops daily, non-invasive, disposable, wearable glucose sensors. It also offers digital diabetes management tools and earlier this year added CGM-guided insulin dose titration to its offerings.

Get the full story at our sister site, Drug Delivery Business News.

The proBEAT sensor. [Image from Nemaura Medical]Nemaura Medical (Nasdaq:NMRD) announced today that it now includes insulin under its DuoPack commercial license agreement.

Loughborough, UK-based Nemaura Medical entered into a commercial agreement in September 2021 with MySugarWatch DuoPack Limited (MSWDL). Under the agreement, Nemaura’s non-invasive, wearable skin patch sensors paired with prescription-only medicines for type 2 diabetes. This created the MySugarWatch-branded “DuoPack.”

Nemaura Medical develops and commercializes non-invasive, wearable diagnostic devices. Its sugarBEAT and proBEAT devices provide continuous glucose monitoring (CGM) plus additional capabilities.

Get the full story at our sister site, Drug Delivery Business News.

[Image from Nemaura Medical]Nemaura Medical (Nasdaq:NMRD) announced that it received a purchase order for 5,000 proBEAT glucose sensor subscriptions.

HealthFleet, a U.S.-based telehealth provider, made the purchase order. It consists of 75,000 proBEAT glucose sensors over an initial five-month period. Nemaura values the deal at $500,000 in revenue, while HealthFleet possesses the option to increase volumes based on customer response.

It marks Loughborough, England-based Nemaura’s first partnership deal in the U.S.

Get the full story at our sister site, Drug Delivery Business News.

Nemaura Medical (NSDQ:NMRD) announced that it intends to offer shares of its common stock and warrants in an underwritten public offering.

The Loughborough, England-based wearable diagnostic device developer for people with diabetes said in a news release that it also expects to grant a 45-day option to purchase up to an additional 15% of the shares of common stock and/or warrants to purchase common stock, according to a news release.

Nemaura, which is currently commercializing the SugarBeat continuous glucose monitor and the Beat diabetes health subscription service, did not disclose the amount of shares and/or warrants it plans to sell, the offering price of the shares and/or warrants or the overall expected proceeds from the offering.

Last week, Nemaura commissioned the integration of data to its ProBeat app set for U.S. launch this year. SugarBeat had its app launched last month. In April, the company announced that the CGM is set to be repurposed fo…

Nemaura Medical (NSDQ:NMRD) announced today that it commissioned the integration of data to its ProBeat app set for U.S. launch this year.

Data from third-party wearable devices can now be integrated into the ProBeat system, which is a wearable, non-invasive glucose monitor designed to gather big data centered around factors that affect blood glucose levels, according to a news release.

Loughborough, England-based Nemaura Medical said its predictive algorithms and artificial intelligence-based feedback and prompts, combined with the introduction of third-party data, can give users access to information that reveals the relationship between various activities and the factors affecting blood glucose levels.

Nemaura’s SugarBeat, which had its app launched last month, is designed for glucose monitoring on smart devices. In April, the company announced that the CGM is set to be repurposed for continuous temperature monitoring (CTM) to match with the Sug…